A method for estimating progression rates in Alzheimer disease.

Area of Science:

• Neurology
• Neuroscience
• Biostatistics

Background:

• Predicting Alzheimer disease (AD) progression is crucial for clinical management, biomarker validation, and therapeutic trial design.
• Early prediction aids in tailoring patient care and optimizing research strategies for AD therapies.

Purpose of the Study:

• To evaluate a calculated early rate of decline (preprogression rate) as a predictor of future disease progression in Alzheimer disease patients.
• To assess the utility of this preprogression rate in stratifying patients based on their disease trajectory.

Main Methods:

• Calculated preprogression rates for 298 Alzheimer disease patients using Mini-Mental State Examination (MMSE) scores and estimated symptom duration.
• Stratified patients into slow, intermediate, and rapid progressors based on their preprogression rates.
• Utilized Cox regression analysis to identify predictors of time to clinically meaningful deterioration (MMSE score drop of ≥5 points).

Main Results:

• Both initial MMSE scores and the calculated preprogression rate were significant predictors of time to clinically meaningful decline.
• Patients stratified as slow, intermediate, and rapid progressors showed significantly different intervals to deterioration.
• The preprogression rate effectively classified patients, with rapid progressors declining fastest.

Conclusions:

• An easily calculable early disease progression rate effectively classifies Alzheimer disease patients.
• This preprogression rate demonstrates good predictive value for disease trajectory, even at initial presentation.
• The findings support the use of this method for patient stratification in clinical and research settings.